Evidence Scanner
Website
Blog
← Docs home
Visualizations
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-09 20:11:41
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 05:55:27
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 06:03:43
Ribociclib plus fulvestrant for advanced breast cancer: Health\u002Drelated quality\u002Dof\u002Dlife analyses from the MONALEESA\u002D3 study \u002D 2026\u002D02\u002D10 06:16:39
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 06:27:10
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 06:36:26
Ribociclib plus fulvestrant for advanced breast cancer: Health\u002Drelated quality\u002Dof\u002Dlife analyses from the MONALEESA\u002D3 study \u002D 2026\u002D02\u002D10 06:41:35
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 06:50:50
Ribociclib plus fulvestrant for advanced breast cancer: Health\u002Drelated quality\u002Dof\u002Dlife analyses from the MONALEESA\u002D3 study \u002D 2026\u002D02\u002D10 06:55:39
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 07:09:58
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 07:19:27
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 07:26:57
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 07:35:07
Ribociclib plus fulvestrant for advanced breast cancer: Health\u002Drelated quality\u002Dof\u002Dlife analyses from the MONALEESA\u002D3 study \u002D 2026\u002D02\u002D10 07:53:52
Ribociclib plus fulvestrant for advanced breast cancer: Health\u002Drelated quality\u002Dof\u002Dlife analyses from the MONALEESA\u002D3 study \u002D 2026\u002D02\u002D10 08:01:57
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 08:29:48
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 08:38:24
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 08:42:59
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 08:50:01
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-10 08:57:25
ribociclib - 2026-02-12 07:30:50
ribociclib - 2026-02-12 07:42:37
ribociclib - 2026-02-12 07:47:50
ribociclib - 2026-02-12 07:49:28
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 07:54:57
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 08:03:46
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 08:14:03
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 08:18:56
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 08:28:39
Ribociclib plus fulvestrant for advanced breast cancer: Health\u002Drelated quality\u002Dof\u002Dlife analyses from the MONALEESA\u002D3 study \u002D 2026\u002D02\u002D12 08:35:04
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 08:51:56
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 08:57:41
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 09:18:23
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 09:26:16
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 09:37:43
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 09:47:06
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:03:50
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:15:07
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:23:24
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:30:24
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:39:54
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:46:38
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 10:54:50
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 11:00:56
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 11:44:37
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 17:02:12
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 17:17:35
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 18:10:21
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 18:45:41
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 19:11:43
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 19:20:25
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 19:28:18
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 20:02:03
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-12 20:14:34
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - 2026-02-13 05:42:09
Dupilumab: Drug information - 2026-02-13 05:45:36
Dupilumab: Drug information - 2026-02-13 05:59:55
Dupilumab: Drug information - 2026-02-13 07:25:33
Dupilumab: Drug information - 2026-02-13 07:35:14
Dupilumab: Drug information - 2026-02-13 07:44:00
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 07:49:24
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 07:57:12
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - 2026-02-13 08:47:24
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 09:33:55
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 09:41:20
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 10:01:59
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 10:05:39
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 11:10:40
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 11:35:02
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 11:39:54
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 12:39:10
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - 2026-02-13 13:30:16
Survival with Olaparib in Metastatic Castration\u005Cu002DResistant Prostate Cancer \u005Cu002D 2026\u005Cu002D02\u005Cu002D13 16:08:46
Visualizations
Pages in this category: